CLOs on the Move

Argentis Pharmaceuticals

www.argentisrx.com

 
arGentis™ Pharmaceuticals, LLC is a private TN based pharmaceutical company with a mid-stage Orphan Drug treatment (ARG201) for late stage diffuse systemic scleroderma (dcSSc). The company is seeking capital or a partner to complete a Pivotal Clinical Trial which will enable obtaining marketing approval in the EU. The Company has a genotype marker (ROT1) that predicts patient response to treatment by oral tolerance for treatments like ARG201 for dcSSc. Furthermore, arGentis™ has a treatment for Rheumatoid arthritis (ARG301) that is in a Phase I Clinical Trial in the US.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.argentisrx.com
  • 1016 W. Poplar Ave. Suite 106-238
    Collierville, TN USA 38017
  • Phone: 901.881.8665

Executives

Name Title Contact Details

Similar Companies

Dripping Springs Pharmacy

Dripping Springs Pharmacy is a Dripping Springs, TX-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Medefil Inc

Medefil Inc is a Glendale Heights, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Shionogi USA Inc

Shionogi USA Inc is a Florham Park, NJ-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Pharm-Aloe Inc

Pharm-Aloe Inc is a Woodford, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ProNAi

ProNAi Therapeutics is a clinical-stage oncology company pioneering a novel class of therapeutics based on its proprietary DNAi technology platform for patients with cancer and hematological diseases. ProNAi`s lead DNAi product candidate, PNT2258, is designed to treat cancers that overexpress BCL2, an important and validated oncogene known to be dysregulated in many types of cancer. ProNAi is pursuing a multi-faceted clinical development strategy designed to efficiently achieve regulatory approval and maximize the commercial opportunity of PNT2258. ProNAi recently initiated "Wolverine", a Phase 2 trial evaluating PNT2258 for the treatment of relapsed or refractory diffuse large B-cell lymphoma.